BlueCrest Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

BlueCrest Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-150,000	Closed	-$1.48M	–	316
2021 Q4	$1.48M	Hold	150,000	–	–	0.05%	207
2021 Q3	$1.49M	Hold	150,000	–	–	0.04%	233
2021 Q2	$1.55M	Hold	150,000	–	–	0.03%	341
2021 Q1	$1.53M	Hold	150,000	–	–	0.03%	501
2020 Q4	$1.71M	Buy	+150,000	New	+$1.59M	0.04%	269

Other funds holding MLTX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

BlueCrest Capital Management's MLTX Position: Q1 2022 in Review

BlueCrest Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2022, closing a stake of 150,000 shares — an estimated $1.48M sold.

BlueCrest Capital Management first reported a position in MLTX in Q4 2020 and held it in 5 quarters. The position peaked at $1.71M in Q4 2020. 27 funds tracked by Wall St. Rank hold MLTX as of Q1 2022.

BlueCrest Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
BlueCrest Capital Management sold 150,000 MoonLake Immunotherapeutics shares in Q1 2022, an estimated $1.48M.
BlueCrest Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 5 quarters.
BlueCrest Capital Management's MoonLake Immunotherapeutics position peaked at $1.71M in Q4 2020.
27 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2022.

Based on BlueCrest Capital Management's 13F filing for Q1 2022, filed 16 May 2022.